Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.59 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.56 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.49 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | XIAP | P98170 | 1/20 | 0.59 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.59 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.51 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27531497 | 1.00 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL216055 | 1.00 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL27531496 | 1.00 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL1098660 | 1.00 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Acetic Acid SCHEMBL28580203 | 0.98 | ALPI (0.58) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL616963 | 0.98 | ALPI (0.61) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL132790 | 0.98 | ALPI (0.61) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL132409 | 0.98 | ALPI (0.61) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Alcohol SCHEMBL28297579 | 0.97 | ALPI (0.56) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7864444 | 0.97 | ALPI (0.59) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118007135-A | Corrosion inhibition method for inhibiting metal corrosion in sulfur-containing medium | 福建理工大学 | 2024-05-10 | — | — | CN | claimed |
| CN-118007135-A | Corrosion inhibition method for inhibiting metal corrosion in sulfur-containing medium | 福建理工大学 | 2024-05-10 | — | — | CN | disclosed |
| EP-3015488-B1 | PRODUCTION METHOD FOR POLYAMINO ACID | TAKEDA PHARMACEUTICALS CO (JP) | 2024-03-06 | — | — | EP | disclosed |
| CN-113845569-B | Synthetic method of pasireotide intermediate | 浙江湃肽生物有限公司南京分公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-113845569-A | Synthetic method of pasireotide intermediate | 浙江湃肽生物有限公司南京分公司 | 2021-12-28 | — | — | CN | disclosed |
| US-10336864-B2 | Production method for poly(amino acid) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20180044472-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-15 | — | — | US | disclosed |
| US-9815938-B2 | Production method for poly(amino acid) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-14 | — | — | US | disclosed |
| WO-2017102802-A1 | RESORCINOL DERIVATIVES FOR THEIR COSMETIC USE | L'OREAL (FR) | 2017-06-22 | — | — | WO | disclosed |
| US-20160177032-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-23 | — | — | US | disclosed |
| WO-1999020606-A2 | PIPERIDINES AND PIPERAZINES AS PLATELET AGGREGATION INHIBITORS | J. URIACH & CIA. S.A. (ES) | 1999-04-29 | — | — | WO | disclosed |
| EP-0730578-A4 | INDOLYL GROUP CONTAINING COMPOUNDS AND THE USE THEREOF TO PROMOTE THE RELEASE OF GROWTH HORMONE(S) | MERCK & CO INC (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5663171-A | FOR USE IN HUMANS OR ANIMALS | MERCK & CO., INC. (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0730578-A1 | INDOLYL GROUP CONTAINING COMPOUNDS AND THE USE THEREOF TO PROMOTE THE RELEASE OF GROWTH HORMONE(S) | MERCK & CO. INC. (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995014666-A1 | INDOLYL GROUP CONTAINING COMPOUNDS AND THE USE THEREOF TO PROMOTE THE RELEASE OF GROWTH HORMONE(S) | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0278787-B1 | A process for enzymatic production of dipeptides | CARLBIOTECH LTD AS (DK) | 1993-10-20 | — | — | EP | disclosed |
| EP-0435887-A1 | RENIN INHIBITORY PEPTIDES CONTAINING MALEAMIDE SUBSTITUENTS | THE UPJOHN COMPANY (US) | 1991-07-10 | — | — | EP | disclosed |
| WO-1990003389-A1 | RENIN INHIBITORY PEPTIDES CONTAINING MALEAMIDE SUBSTITUENTS | THE UPJOHN COMPANY (US) | 1990-04-05 | — | — | WO | disclosed |
| WO-1988006187-A1 | A PROCESS FOR ENZYMATIC PRODUCTION PRODUCTION OF DIPEPTIDES | CARLSBERG BIOTECHNOLOGY LTD. A/S (DK) | 1988-08-25 | — | — | WO | disclosed |
| EP-0278787-A1 | A process for enzymatic production of dipeptides | CARLBIOTECH LTD. A/S (DK) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044472-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | PGA5, ENPEP, PARG | PTGS1 412/4885MMP8 4693/4885HDAC8 3197/4885 |
| US-10336864-B2 | Production method for poly(amino acid) | PGA5, ENPEP, PARG | PTGS1 412/4885MMP8 4693/4885HDAC8 3197/4885 |
| US-20160177032-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | PGA5, ENPEP, PARG | PTGS1 412/4885MMP8 4693/4885HDAC8 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.